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Introduction
Myeloproliferative neoplasms (MPNs) are a 
group of hematopoietic stem cell disorders char-
acterized by clonal proliferation of myeloid-line-
age cells. Classic MPNs include polycythemia 
vera (PV), essential thrombocythemia (ET), pri-
mary myelofibrosis (PMF), and chronic myeloid 
leukemia (CML) [Tefferi and Vardiman, 2008]. 
CML is defined by a reciprocal translocation 
of chromosomes 9 and 22, resulting in the 
Philadelphia chromosome (Ph), and will not be 
discussed in this article. The Ph-negative MPNs, 
which include PV, ET, and PMF, share many 
common clinical and molecular characteristics, 
including increased risk of thrombosis and leuke-
mic transformation.
Arterial and venous thromboses are a major cause 
of morbidity in Ph-negative MPNs. Venous throm-
bosis may occur at unusual anatomic sites, such 
as splanchnic vein thrombosis (SVT) or cerebral 
sinus thrombosis. SVT refers to thrombosis forma-
tion in the portal venous system (portal vein 
thrombosis, PVT), hepatic venous system Budd-
Chiari syndrome (BCS), splenic venous system, or 
mesenteric venous system. SVTs are rare, with 
large epidemiological studies estimating the inci-
dence rate to be 0.7 per 100,000 patients per year 
for PVTs and 0.8 per million patients per year for 
BCS [Rajani and Almer, 2009; Rajani et al. 2010]. 
This is significantly lower than the incidence rate 
of deep venous thromboses (DVTs), which is esti-
mated to be roughly 100 per 100,000 patients per 
year in the United States [White, 2003]. 
Interestingly, MPNs are the most common under-
lying prothrombotic disorder found in patients 
diagnosed with SVT, in the absence of local incit-
ing factors such as liver cirrhosis or nearby malig-
nancy. In patients with BCS specifically, systemic 
factors, such as an underlying MPN, are more 
common than local factors [Ageno et  al. 2014]. 
The strong association between SVT and MPN 
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has led to recommendations to screen for MPN 
when SVT is diagnosed [Smalberg et al. 2012].
The reason for the association between SVT and 
MPN is not immediately clear. Age, sex, concom-
itant hypercoagulable disorders, and the presence 
of the JAK2 V617F mutation have all been impli-
cated in the pathogenesis of SVT in MPN. 
Improving our understanding of the mechanisms 
that predispose to SVT formation is an area of 
ongoing research. The purpose of this article is to 
review the clinical and molecular risk factors for 
MPN-associated SVT, with particular focus on 
the possible disease mechanisms of SVT forma-
tion in MPN patients. The treatment and man-
agement of MPN-associated SVTs have been 
discussed extensively in two recently published 
reviews [Sekhar et  al. 2013; De Stefano et  al. 
2015], and will not be discussed in this review.
Prevalence of SVT in MPNs
The prevalence of a venous thromboembolism 
(VTE) at the time of MPN diagnosis is estimated 
to be approximately 11–39% for PV, 8–29% for 
ET, and 3–7% for PMF [Barbui et al. 2010; Kreher 
et al. 2014]. SVTs represent a fraction of VTE in 
MPNs, with an estimated prevalence of 5–10% in 
PV patients and 9–13% in ET patients [Anger 
et al. 1989; De Stefano et al. 2008]. SVTs occur 
even less frequently in PMF patients, with an esti-
mated prevalence rate of 0.6–1% [Anger et  al. 
1989; Barbui et al. 2010]. PVT is the most com-
mon type of SVT (40%), while BCS is the least 
common (5%) [De Stefano et al. 2008; Smalberg 
et  al. 2012]. Conversely, in patients presenting 
with SVT, MPNs are the most common underly-
ing prothrombotic disorder. Prevalence rates of 
MPN in SVT have ranged from 5–70%, with a 
large meta-analysis estimating that 40% of BCS 
patients and 30% of PVT patients are subsequently 
found to have an underlying MPN [Smalberg et al. 
2012; Sekhar et al. 2013]. PV makes up the largest 
subgroup in patients with SVT (27%), and PMF 
makes up the smallest subgroup (13%) [Smalberg 
et  al. 2012]. Table 1 summarizes the prevalence 
rates of SVTs in MPNs, and vice versa.
Clinical factors associated with SVT in MPN
The proportion of SVT among all VTEs is dis-
proportionately higher in MPN patients com-
pared with the general population, as SVTs make 
up an estimated 7.5% of total VTE cases [De 
Stefano et al. 2008]. In comparison, the frequency 
of DVTs and PEs in the general population is 400 
times greater than that of SVTs [Deitelzweig et al. 
2011]. Interestingly, the risk factors associated 
with these unusual thromboses are different from 
the risk factors traditionally associated with all-
cause arterial and venous thrombosis. Figure 1 
compares the known clinical risk factors of SVTs 
with those of all-cause VTE.
Age and sex. The best established risk factors for 
thrombosis in MPN are age >60 years and prior 
history of thrombosis [Marchioli et  al. 2005; 
Kreher et  al. 2014; Tefferi and Barbui, 2015]. 
Analysis of 1638 PV patients collected in the 
ECLAP (European Collaboration on Low-dose 
Aspirin in Polycythemia vera) trial showed that 
only advanced age (>60 years), previous venous 
thrombosis (but not arterial thrombosis), and 
intermittent claudication demonstrated a statisti-
cally significant increased risk of a subsequent 
VTE [Landolfi et al. 2007]. In a multivariate anal-
ysis of 891 patients with ET, male sex was also 
found to be associated with increased venous 
thrombosis [Carobbio et  al. 2011]. However, 
sex was not found to have a significant effect on 
VTE in PV patients, nor has this finding been 
demonstrated in other epidemiological studies 
[Marchioli et al. 2005; Landolfi et al. 2007].
In contrast, MPN patients with SVTs are pre-
dominantly younger and female. Lussana and 
colleagues evaluated the prevalence of thrombosis 
in JAK2-mutated patients younger than 40 years 
Table 1. (a) SVTs in patients with MPNs compared 
with the general population. (b) Prevalence rates of 
MPNs in patients found to have an SVT.
(a) Prevalence rates of SVTs.
 Within MPNs Within general 
population
PVT 6100 per 100,000 3.7 per 100,000
BCS 1200 per 100,000 0.14 per 100,000
(b) Prevalence rates of MPNs
 Within PVT Within BCS
 40% 30%
Sources: De Stefano et al. [2008] - 6100/100,000 PVT 
within MPN; Anger et al. [1989] - 1200/100,000 BCS within 
MPN; Rajani and Almer [2009] - 0.14 per 100,000 BCS 
within general population; Rajani et al. [2010] - 3.7 per 
100,000 PVT within general population; Smalberg et al. 
[2012] - prevalence rates of MPNs within PVT and BCS.
BCS, Budd-Chiari syndrome; MPN, myeloproliferative 
neoplasms; PVT, portal vein thrombosis; SVT, splanchnic 
vein thrombosis.
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of age. In this cohort of 538 patients, venous 
thrombosis was significantly higher than arterial 
thrombosis (47% versus 34%), and SVTs made 
up 79% (26 out of 33) of these VTE cases 
[Lussana et al. 2014]. This is in contrast with the 
observation that arterial thromboses rates are 2–3 
times higher than venous thrombosis rates in the 
total MPN population [Barbui et  al. 2013]. In 
addition, the proportion of SVTs in this younger 
population was much higher than in the total 
MPN population (79% compared with 7.5%) 
[De Stefano et  al. 2011; Lussana et  al. 2014]. 
Another study, by Stein and colleagues, com-
pared disease characteristics in a cohort of 
younger (age < 45 years) and older (age > 65 
years) MPN patients. The investigators found 
that although younger patients had a comparable 
rate of all-cause thrombosis, SVTs occurred sig-
nificantly more frequently (13% compared with 
2%) in patients younger than 45 years of age 
[Stein et al. 2013]. The younger cohort was also 
predominantly female, and had a significantly 
lower JAK2 allele burden [Stein et  al. 2010, 
2013]. The observation that SVTs are signifi-
cantly more frequent in women compared with 
men was also noted in the study by Lussana and 
colleagues [Lussana et al. 2014]. There are lim-
ited data to suggest that other clinical or labora-
tory risk factors, such as a history of prior 
thrombosis or elevated cell counts, increase the 
risk of SVTs.
Thrombophilic disorders. Hypercoagulable disor-
ders such as antiphospholipid syndrome, protein 
C or S deficiency, factor V Leiden mutation, or 
antithrombin deficiency are independent risk 
factors for SVT [Kiladjian et  al. 2008]. In one 
study of 40 patients with SVTs, it was found that 
38% of patients had an additional risk factor to 
MPN, including a hypercoagulable disorder, par-
oxysmal nocturnal hemoglobinuria (PNH), auto-
immune disorder (such as a connective tissue 
disease), or ulcerative colitis [De Stefano et  al. 
2011]. Overall, it has been estimated that multi-
ple concurrent risk factors are present in 10–46% 
of BCS patients and 10–64% of PVT patients 
[De Stefano et al. 2011].
Environmental risk factors. Oral contraceptive 
(OCP) use has been implicated as a predisposing 
risk factor for VTEs and cerebral sinus thrombo-
sis [Vandenbroucke et al. 1994; Stam, 2005]. It 
is unclear of the extent to which OCP use 
increases the risk of SVT formation, given the 
widespread use of OCPs and the presence of 
concomitant hypercoagulable disorders. In one 
study examining the etiological factors in BCS, 
Smalberg and colleagues identified OCP use in 
52% of the 26 female patients. However, these 
patients often had an additional prothrombotic 
disorder, and the authors did not specify which 
combination of etiological factors were present 
[Smalberg et  al. 2006]. An additional study 
examining OCP use and VTE found that nine 
OCP-users had developed an SVT, of which two 
were JAK2 positive [Grandone et al. 2008]. Nei-
ther of these two women had a concomitant 
hypercoagulable disorder, although a thrombo-
philia was present in five of the remaining JAK2-
negative patients [Grandone et  al. 2008]. OCP 
use has been shown to increase the risk of VTE 
in the presence of an inherited thrombophilia, 
and it is possible that SVT risk may be similarly 
increased in MPN patients who use OCPs [Van-
denbroucke et al. 1994]. This may also partially 
explain the observation that females are more 
likely to develop an MPN-associated SVT; how-
ever, larger epidemiological studies are needed 
to potentially establish an association between 
MPNs, SVTs, and OCP use.
There are few data to suggest that other envi-
ronmental exposures play a significant role in 
MPN-associated SVT. Some research has sug-
gested that smoking, along with other general 
cardiovascular risk factors, increases the rate of 
arterial thrombosis, but the data are conflicting 
[Falanga and Marchetti, 2014]. There are few 
data, however, regarding whether these risk fac-
tors apply to venous thrombosis, and specifi-
cally SVT.
Figure 1. Venn diagram comparing cited clinical risk 
factors for SVTs and all-cause VTEs. Bold indicates 
the most validated risk factors.
PVT, portal vein thrombosis; SVT, splanchnic vein 
thrombosis; VTE, venous thromboembolism.
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The JAK2 V617F mutation in MPN-associated 
SVT
JAK2 is a tyrosine kinase that initiates intra- 
cellular signaling in the JAK/STAT pathway via 
binding to receptors for erythropoietin, throm-
bopoietin, granulocyte colony-stimulating factor, 
and granulocyte macrophage colony-stimulating 
factor [James, 2008; Oh and Gotlib, 2010]. The 
JAK2 V617F mutation causes constitutive activa-
tion of the JAK2 kinase, resulting in subsequent 
phosphorylation of STAT proteins, ultimately 
leading to overproduction of myeloid-lineage 
cells [Campbell and Green, 2006; Oh and Gotlib, 
2010]. The identification of the JAK2 V617F 
mutation in nearly 95% of PV cases and 50–60% 
of ET and PMF cases has led to its incorporation 
into the diagnostic evaluation of MPNs [Campbell 
and Green, 2006]. Current guidelines recom-
mend testing for JAK2 mutations in any patient 
suspected to have an MPN [Ageno et al. 2016].
JAK2 mutation in SVT in the absence of overt 
MPN
An estimated 40% of BCS patients and 28% of 
PVT patients also test positive for the JAK2 
V617F mutation [Smalberg et al. 2012]. For this 
reason, in any patient presenting with an SVT, 
JAK2 testing is recommended as part of the ini-
tial work-up for MPN. This has led to the obser-
vation that a significant proportion of SVT 
patients (15–17%) test positive for JAK2 V617F, 
but do not otherwise meet WHO criteria for an 
MPN [Smalberg et al. 2012]. Indeed, one study 
estimated that testing for JAK2 can identify an 
additional 30% of MPN patients who do not 
otherwise have overt evidence of disease [De 
Stefano et al. 2007]. The most frequently cited 
reason for the absence of elevated blood counts 
is the presence of portal hypertension and sple-
nomegaly that result from SVT and MPN, which 
can lead to sequestration of blood cells as well as 
hemodilution, thus ‘masking’ the clinical pheno-
type of MPN. Investigators have found that 
while ‘masked’ patients display lower hemo-
globin levels, they also have increased plasma 
volumes secondary to splenomegaly or SVT for-
mation [Lamy et al. 1997].
It is also possible that SVT patients with JAK2 
V617F, but no overt clinical features of MPN, 
may represent a distinct subtype of MPN or an 
early phase of the disease. Up to 70% of patients 
presenting with SVT do not carry a prior diagnosis 
of MPN, and it has been estimated that SVTs 
represent the first thrombotic event in 7.5% of 
patients with PV and ET [De Stefano et al. 2008; 
Hoekstra et al. 2011]. SVTs may thus occur dur-
ing an early stage of MPN, prior to the develop-
ment of the clinical phenotype. For instance, one 
meta-analysis found that 21 out of 41 JAK2-
positive patients without an MPN diagnosis at the 
time of SVT presentation subsequently developed 
an MPN during follow up [Dentali et al. 2009]. A 
more recent study looking at long-term outcomes 
of SVT patients also observed that 9 out of 13 
JAK2-positive patients were found to have an 
MPN after 64 months [Colaizzo et  al. 2013]. 
These findings suggest that in these patients, 
SVTs represent an early manifestation of their dis-
ease. In Colaizzo and colleagues’ study, six out of 
the eight SVT patients who were initially JAK2-
negative were found to be JAK2-positive with 
clinical symptoms of an MPN by 21 months 
[Colaizzo et al. 2013]. Such observations suggest 
either that a disease process was already in exist-
ence before the occurrence of the JAK2 mutation, 
or that the initial JAK2 V617F allele burden had 
not reached a detectable level by conventional 
laboratory testing at the time of SVT diagnosis. 
The hypothesis that SVTs are early manifestations 
of MPN may partially account for the finding that 
MPN-associated SVT patients tend to be younger 
with lower JAK2 V617F allele burdens.
The hypothesis that SVT patients represent an 
earlier stage of MPN disease has important impli-
cations in evaluating the underlying molecular 
pathogenesis of MPNs. It has been hypothesized 
that blood cancers arise from stepwise genetic 
mutations that confer survival and growth advan-
tages to hematopoietic stem cells, eventually 
resulting in clonal hematopoiesis and malignancy 
[Xie et al. 2014]. While early mutations may allow 
clonal expansion, cooperating mutations that 
occur later enable development of a hematopoi-
etic cancer. JAK2-positive patients without clini-
cal findings of an MPN may lack these cooperating 
mutations that result in blood cell proliferation. 
For instance, a significant percentage of MPN-
associated mutations, including JAK2 V617F, 
have been found in elderly individuals without 
overt evidence of an MPN [Genovese et al. 2014; 
Xie et al. 2014]. These individuals, however, are 
at an increased risk of developing a subsequent 
hematologic malignancy and cardiovascular mor-
tality [Jaiswal et al. 2014]. These data suggest that 
mutations such as JAK2 V617F can be initiating 
events that may ultimately lead to the develop-
ment of overt malignancy. Similarly, in SVT 
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patients who subsequently develop MPNs, it is 
possible that the development of thrombosis 
reflects pathology related to an initiating clone. 
The progression to overt MPN, including ele-
vated cell counts, may only become apparent 
upon acquisition of subsequent mutations. These 
patients with positive JAK2 mutation status may 
thus be considered a ‘pre-malignant’ state, and as 
such represent a unique population for studying 
the clonal evolution of MPNs.
Prevalence of the JAK2 V617F in MPN-
associated SVTs
There is a high prevalence of the JAK2 V617F 
mutation found in SVT, and the percentage is 
even higher when restricted to patients meeting 
MPN criteria with SVT [Patel et  al. 2006]. An 
estimated 71–100% of patients with overt MPN 
and SVT test positive for JAK2 V617F, which is 
significantly higher than the prevalence of the 
JAK2 mutation in MPN patients with other 
VTEs [Austin and Lambert, 2008]. A systematic 
review of 24 studies and 3123 patients found that 
JAK2 V617F conferred a significantly increased 
risk of SVT formation, with an odds ratio of 54 
[Dentali et al. 2009]. In addition, while the mean 
prevalence of the JAK2 mutation in SVTs was 
high (33%, similar to rates reported in the litera-
ture), the mean prevalence of JAK2 V617F in 
other VTEs was low (0.88–2.57%) [Dentali et al. 
2009]. Despite these associations, one study 
observed that young females tended to have a 
lower JAK2 mutant allele burden, even though 
they are at higher risk for SVTs [Stein et al. 2010]. 
The findings of increased incidence of the JAK2 
mutation but lower allele burden may suggest an 
‘all or nothing’ effect of the JAK2 mutation, 
which is perhaps subsequently modified by addi-
tional clinical risk factors such as concomitant 
hypercoagulable disorders, as discussed in the 
previous section.
JAK2 V617F mutation as a molecular driver of 
SVT formation
The majority of SVTs (with the exception of BCS) 
are due to local perturbations in the venous sys-
tem, such as cirrhosis or nearby malignancy. It is 
possible that the JAK2 mutation itself may have 
local effects on the splanchnic venous system. This 
venous system is unique in that blood flow velocity 
is much slower, leading to prolonged interactions 
between blood and sinusoidal endothelial cells 
[Aird, 2007a]. In vitro models have shown that PV 
red blood cells demonstrate increased adhesion to 
endothelial laminin, and this adhesiveness is par-
ticularly increased at low shear rates [Wautier and 
Wautier, 2013]. Furthermore, the portal venous 
system is exposed to gut-derived inputs, altering its 
immunogenicity such that vessels are more vulner-
able to activated platelets and states of high viscos-
ity such as increased cell count [Aird, 2007b]. 
These characteristics may put the splanchnic 
venous system at particular risk to perturbations 
caused by JAK2 V617F, which affect not only cell 
quantity, but cell quality.
The JAK2 mutation has a widespread effect on 
the hematologic system. JAK2-mutant megakary-
ocytes display hypersensitive signaling and 
increased mobility and aggregation [Hobbs et al. 
2013]. Studies with JAK2 V617F knock-in mice 
have demonstrated that megakaryocytes carrying 
the JAK2 mutation show greater chemotaxis along 
migration assays, as well as increased pro-platelet 
formation in response to low-level thrombopoietin 
signaling [Hobbs et  al. 2013]. JAK2-positive 
platelets also display increased in vitro thrombus 
formation when exposed to collagen-coated sur-
faces, although Lamrani and colleagues found 
decreased platelet reactivity when tested in a dif-
ferent mouse model [Hobbs et al. 2013; Lamrani 
et al. 2014]. However, accelerated platelet aggre-
gation occurred when studied in vivo in artificially 
injured blood vessels [Lamrani et al. 2014]. Blood 
samples taken from JAK2-positive patients with 
MPN also show significantly higher levels of solu-
ble P-selectin, a marker of platelet activation, 
compared with JAK2-negative patients with MPN 
[Robertson et al. 2007].
Leukocyte activation also contributes to the pro-
coagulant milieu, as studies have shown that 
markers of polymorphonuclear activation corre-
late with markers of hypercoagulability in ET and 
PV patients [Falanga et  al. 2005]. It is thus 
believed that activated leukocytes can cause secre-
tion of pro-coagulant factors, leading to further 
platelet activation and aggregation. In JAK2-
positive patients, the level of both leukocyte and 
platelet activation increases with higher JAK2 
mutational burden, and an epidemiological study 
by Barbui and colleagues found that the highest 
incidence of thrombosis was seen in PMF patients 
with both leukocytosis and the JAK2 mutation 
[Arellano-Rodrigo et al. 2006; Barbui et al. 2013]. 
Red blood cells also display increased adhesion to 
the endothelium in PV patients [Wautier and 
Wautier, 2013]. This effect may be mediated by 
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aberrations in JAK/STAT signaling, as JAK2 
V617F can induce phosphorylation of glycopro-
teins critical for red blood cell adhesion [De 
Grandis et al. 2013]. Taken together, these find-
ings suggest that the JAK2 mutation leads to dis-
tinct changes in hematopoietic cells that increase 
the likelihood of thrombus formation.
The propensity for SVT development in MPN is 
also potentially due to differential regulation of 
hemostasis in specific vascular beds. Endothelial 
cells are integrally involved in regulating throm-
bosis, and are capable of expressing both pro- 
and anticoagulant factors depending on both the 
environmental milieu and cell type [Rosenberg 
and Aird, 1999]. This is supported by observa-
tions that MPNs are associated with specific ana-
tomical locations within the splanchnic venous 
system. In MPN patients with BCS, for example, 
thrombosis tends to occur in the large, hepatic 
veins, while BCS patients with other hypercoag-
ulable disorders tend to have thrombosis involv-
ing the inferior vena cava [Valla, 2015]. Signaling 
pathways specific to the splanchnic venous sys-
tem can then cause unique interactions with 
mutated blood cells. For instance, in PNH, a 
complement-mediated disorder that also pre-
sents with increased susceptibility to SVT, the 
presence of gut-derived antigens in the splanch-
nic veins may cause higher local activation of 
complement, with subsequent higher rates of 
hemolysis and thrombotic activation [van Bijnen 
et al. 2012].
Mutant endothelial cells may also contribute to 
SVT pathogenesis. Liver endothelial cells isolated 
from two BCS patients have been found to carry 
the JAK2 mutation [Sozer et al. 2009]. Further 
studies have identified the JAK2 mutation in 
spleen endothelial cells and circulating endothe-
lial progenitor cells [Teofili et al. 2011; Rosti et al. 
2013]. JAK2 V617F-mutated endothelial pro-
genitor cells also displayed increased adherence 
to normal mononuclear cells, and were found to 
abnormally activate the JAK/STAT pathway 
[Teofili et  al. 2011]. These findings provide a 
framework in which potentially aberrant endothe-
lial cells in the splanchnic venous system interact 
with aberrant blood cells, eventually leading to 
the formation of SVT. The exact mechanism of 
how alterations in the endothelium lead to SVT is 
still unclear, and warrants further investigation. 
Given the unique environment of the splanchnic 
venous system, it is likely that the mechanisms of 
SVT formation differ from the mechanisms of 
arterial and DVT, accounting for the difference in 
risk factors.
Other molecular drivers of MPN-associated 
SVT
Although the JAK2 mutation plays a significant 
role in MPN in SVT, approximately 14–20% of 
SVT patients with MPN are JAK2-negative 
[Kiladjian et  al. 2008; Smalberg et  al. 2012]. In 
terms of clinical risk factors, JAK2-negative 
patients with MPN/SVT are not statistically dif-
ferent from their JAK2-positive counterparts 
[Kiladjian et al. 2008]. This leads to the question 
of whether there are other mutations that can 
account for the prothrombotic state. Specifically, 
several mutations with increased incidence in 
MPN have been identified, and only recently have 
investigators evaluated these mutations in SVT.
CALR mutations
The CALR gene encodes for calreticulin, a multi-
functional protein that regulates calcium signal-
ing and protein folding in the endoplasmic 
reticulum and cytoplasm [Johnson et  al. 2001]. 
Only recently has a mechanism for CALR-mutant 
MPN pathogenesis been proposed. A series of 
papers demonstrated that mutated calreticulin is 
able to induce MPN phenotypes in mice through 
interaction with the thrombopoietin receptor 
(MPL) [Araki et al. 2016; Chachoua et al. 2016; 
Elf et al. 2016; Marty et al. 2016]. Mutated cal-
reticulin has been shown to bind preferentially to 
MPL, resulting in thrombopoietin-independent 
activation of MPL with subsequent stimulation of 
the JAK/STAT pathway [Araki et  al. 2016; 
Chachoua et al. 2016; Elf et al. 2016; Marty et al. 
2016]. The specificity of mutant calreticulin 
interaction with MPL accounts for the findings 
that CALR mutations are largely absent in PV, 
but found in 30% of all ET and PMF patients, 
and 70–80% of JAK2-negative ET or PMF 
[Klampfl et  al. 2013; Nangalia et  al. 2013]. 
Compared with JAK2, CALR-mutant patients 
tend to have increased platelet counts, lower 
hemoglobin and white cell counts, as well as 
decreased rates of thrombosis, with a more indo-
lent disease course [Nangalia et al. 2013].
How or whether CALR mutations induce SVT 
susceptibility is less clear. Despite the relatively 
high frequency of CALR mutations in MPNs, 
recent studies have failed to find an increased 
incidence of CALR mutations in SVT patients. 
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CALR mutations have been identified in 0–2% of 
SVT, with an estimated total prevalence of 
approximately 0.9% of cases [Castro et al. 2015; 
Colaizzo et  al. 2015; Haslam and Langabeer, 
2015; Iurlo et  al. 2015; Marzac et  al. 2015; 
Plompen et al. 2015; Roques et al. 2015; Turon 
et al. 2015]. Given its relatively low prevalence, 
testing for CALR is not generally recommended 
in patients with SVT [Colaizzo et  al. 2015]. 
Furthermore, its rarity suggests that it is not a 
major contributor to SVT formation, a fact con-
sistent with the observation that CALR-mutated 
patients exhibit decreased rates of thrombosis 
overall [Rumi et al. 2014].
MPL mutations
Mutations in the MPL gene are the third most 
commonly tested for mutation after JAK2 and 
CALR in MPN patients. MPL encodes for the 
thrombopoietin receptor, and mutations expect-
edly cause abnormalities in megakaryocyte and 
platelet production. The most common muta-
tions result in an amino acid substitution (either 
lysine or leucine) at the 515 position (MPL 
W515), are found in approximately 5% of ET/
PMF patients, and are mutually exclusive to 
JAK2 and CALR mutations [Pikman et al. 2006; 
Rumi et al. 2013]. MPL-mutant patients tend to 
be older, with lower cell counts compared with 
JAK2 and CALR-positive patients [Beer et  al. 
2008]. MPL mutations have not been shown to 
confer significant prognostic impact, and patients 
do not have differing risks of thrombosis or major 
hemorrhage [Beer et al. 2008]. However, similar 
to CALR, MPL W515 mutations are rare in SVT, 
with incidence rates even less than CALR 
[Bergamaschi et  al. 2008; Kiladjian et  al. 2008; 
Jadli et al. 2012; Smalberg et al. 2012; Colaizzo 
et al. 2015]. This may be related to the overall low 
prevalence of MPL in MPNs, but there is no evi-
dence to suggest that MPL-positive patients have 
higher rates of SVTs.
The JAK2 46/1 haplotype
The JAK2 46/1 haplotype has recently been 
found to be associated with JAK2-positive MPNs, 
and it is believed that the JAK2 V617F mutation 
arises specifically on the 46/1 allele [Jones et al. 
2009]. Its role in SVT formation is controversial, 
with some studies showing that the haplotype is 
an independent risk factor for SVT development 
in JAK2 V617F patients [Colaizzo et al. 2010a; 
Smalberg et al. 2011], and some studies showing 
only a weak association [Kouroupi et al. 2011]. A 
recent meta-analysis of 26 observational studies 
evaluated the risk of MPN with the JAK2 haplo-
type, and found that the haplotype was signifi-
cantly increased in MPN and SVT patients. In 
JAK2-negative patients, however, the haplotype 
did not confer an additional risk of SVT [Li et al. 
2014]. The increased risk of SVT with the 46/1 
haplotype may be due to an interaction of the 
haplotype with the JAK2 V617F mutation, rather 
than the haplotype itself.
Additional mutations in MPN-associated SVTs
Approximately 10% of MPN patients are ‘tri-
ple-negative’ and do not harbor JAK2, CALR, 
or MPL mutations [Tefferi et  al. 2014]. 
Additional mutations are found in varying fre-
quencies in PV, PMF, and ET patients, 
although they tend not to be mutually exclusive 
with JAK2, CALR, MPL mutations, or with 
each other. These mutations include TET2, 
DNMT3A, EZH2 and ASXL1, and are involved 
in DNA methylation and chromatin structuring 
[Delhommeau et  al. 2009; Grand et  al. 2009; 
Ernst et  al. 2010; Abdel-Wahab et  al. 2011]. 
The specific role of these mutations in driving 
MPN disease formation is not fully understood. 
As discussed previously, SVT patients may be 
an ideal population for investigating the role of 
precursor genes and initiating mutations, as 
these patients may present at an early stage of 
MPN disease evolution. For instance, TET2 is 
a tumor suppressor gene which plays a key role 
in DNA methylation, and mutations in TET2 
have been identified in up to 12% of MPN 
patients, including both JAK2-positive and 
JAK2-negative MPNs [Delhommeau et  al. 
2009]. In the hematopoietic stem cells of 
patients with both JAK2 and TET2 mutations, 
the TET2 mutation could often be found in the 
absence of the JAK2 mutation, suggesting the 
acquisition of TET2 before JAK2 [Delhommeau 
et  al. 2009]. In surveying SVT patients, how-
ever, only a minority (3/23) of SVT patients 
tested positive for TET2, while all were JAK2 
positive [Colaizzo et al. 2010b]. A larger study 
of 43 BCS patients identified 6 patients with a 
deleterious TET2 mutation; however, only 3 
were JAK2-negative and none of these 3 
patients developed an overt MPN [Westbrook 
et al. 2012]. Based on the studies by Colaizzo 
and colleagues and Westbrook and colleagues, 
the prevalence of TET2 in SVTs is roughly 
14%, which is similar to the prevalence rate of 
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TET2 in all MPNs [Delhommeau et al. 2009]. 
While TET2 is found more frequently than 
CALR and MPL in SVT, its frequent co-occur-
rence with JAK2 and lower prevalence rate sug-
gests a limited role in SVT formation. Further 
investigations for mutations present in JAK2-
negative SVT patients are limited. A small 
study of 25 cases of JAK2-negative BCS found 
no patients with IDH1 or IDH2 mutations [Jadli 
et al. 2012].
Table 2 summarizes the prevalence of the most 
common MPN-associated mutations in SVTs and 
all MPNs. In light of the existing literature, there 
seems to be a lack of evidence to suggest that these 
other mutations are associated with SVT forma-
tion in MPN, despite the finding that 14–20% of 
SVT patients with an MPN are JAK2-negative 
[Kiladjian et al. 2008; Smalberg et al. 2012]. The 
existence of a precursor mutation to JAK2 V617F 
critical to SVT pathogenesis has yet to be identi-
fied. Additional research examining the clinical 
and molecular differences between JAK2-positive 
and JAK2-negative patients with SVT is needed 
to further elucidate the driving mechanisms of 
SVT formation and MPN disease progression.
Future directions and conclusion
The development of SVTs in MPN is multifacto-
rial and likely includes both environmental and 
host genetic factors. Risk factors for the develop-
ment of SVT in MPN patients include the JAK2 
V617F mutation, young age, female sex, and the 
presence of concomitant hypercoagulable disor-
ders. Intrinsic characteristics of the splanchnic 
venous bed may predispose to thrombotic inter-
actions with atypical blood cells, which are modi-
fied by JAK2 V617F or unknown precursor 
mutations. Furthermore, the mechanisms that 
cause SVT formation likely differ from the mech-
anisms that cause arterial and DVT, accounting 
for the differences in risk factors. There is little 
evidence to suggest that other known genetic 
alterations implicated in MPN pathogenesis, such 
as CALR, MPL, or the JAK2 46/1 haplotype, are 
critical for SVT formation. Given that SVT 
patients may present at an early stage of MPN, 
identifying common mutations may shed light on 
the molecular pathogenesis of MPN disease 
development and progression.
Research into understanding the occurrence of 
SVTs in MPNs also has important implications 
for treatment and prognosis. Identifying patients 
most at risk for SVT can prevent considerable 
morbidity and mortality. Investigation into the 
use of JAK2 inhibitors to decrease the risk of 
future thrombosis is already under way [Keohane 
et al. 2015]. Future directions for research include 
better characterization of MPN patients with and 
without SVTs, and the development of a database 
of such phenotypes. In particular, investigating 
differences between JAK2-positive and JAK2-
negative patients can better clarify the role of 
JAK2 V617F in thrombosis formation.
In summary, SVTs occur in a unique subset of 
MPN patients, and often present with little overt 
MPN disease characteristics. Understanding the 
association between SVTs and MPNs can pro-
vide insight not just on possible mechanisms of 
thrombosis, but also the pathophysiology of dis-
ease evolution.
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Table 2. Prevalence of MPN-associated mutations 
in SVT and MPN patients. JAK2 makes up the 
highest proportion of patients, while CALR and MPL 
have very low prevalence rates in SVTs. TET2 is 
found at higher prevalence rates but is not mutually 
exclusive with JAK2.
SVT patients MPN patients
JAK2 33% 95% in PV; 60% in ET 
and PMF
CALR 0.9% 30% in ET and PMF
MPL 0.7% 5% in ET and PMF
Other  
 TET2 14% 12%
Sources: MPL- 0.7% in SVT, JAK2- 33% in SVT patients- 
Smalberg et al. [2012]; CALR- 0.9% in SVT patients- De 
Stefano et al. [2015]; MPL- 0.7% in SVT- Bergamaschi 
et al. [2008]; CALR- 0.9% in SVT patients- Colaizzo et al. 
[2015]; MPL- 0.7% in SVT- Kiladjian et al. [2008]; MPL- 
0.7% in SVT, TET2- 14% in SVT- Jadli et al. [2012]; CALR- 
0.9% in SVT patients- Turon et al. [2015]; TET2- 14% in 
SVT- Westbrook et al. [2012]; TET2- 14% in SVT- Colaizzo 
et al. [2010b]; 12% in MPN- Delhommeau et al. 2009; 5% 
in ET and PMF - Pikman et al. 2006; 95% in PV, 60% in 
ET/PMF- Campbell and Green 2006; 30% in ET and PMF- 
Klampf et al. 2013.
ET, essential thrombocythemia; MPN, myeloproliferative 
neoplasms; PMF, primary myelofibrosis; PV, polycythe-
mia vera; SVT, splanchnic vein thrombosis.
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